Sertraline versus other anti-depressive agents for depression

Improving reproducibility by using high-throughput observational studies with empirical calibration

“…Our result set correctly identified findings (1) through ( 4), as discussed in the electronic supplementary material-implying substantial but not perfect agreement with the literature. Electronic supplementary material, figure S3 also compares our results for finding (1) to estimates from RCTs reported in a systematic review on the topic [25], showing agreement as well as greater precision in our estimates due to the much larger sample size.…”

Improving reproducibility by using high-throughput observational studies with empirical calibration

“…Our result set correctly identified findings (1) through ( 4), as discussed in the electronic supplementary material-implying substantial but not perfect agreement with the literature. Electronic supplementary material, figure S3 also compares our results for finding (1) to estimates from RCTs reported in a systematic review on the topic [25], showing agreement as well as greater precision in our estimates due to the much larger sample size.…”

Pitfalls in Geriatric Prescribing: Antidepressants and Extreme Sedation

“…On acute use, sertraline can selectively block serotonin reuptake and can increase serotonin stimulation of somatodendritic 5HT1 but has only weak effects on norepinephrine and neuronal dopamine uptake [11]. However, there is evidence that sertraline has a benefit over other classes of antidepressants in terms of safety or tolerability for the acute phase of severe depression treatment [12].…”

Paroxetine versus other anti-depressive agents for depression

“…To shed light on the field of AD trials and treatment of major depressive disorder, a group of researchers agreed to join forces under the rubric of the Meta-Analyses of New Generation Antidepressants Study Group (MANGA Study Group) to systematically review all available evidence for each specific newer antidepressant. We have up to now completed an individual review for fluoxetine , published the protocols for sertraline (Malvini 2006), fluvoxamine (Omori 2006) and mirtazapine (Watanabe 2007), and a number of other reviews are now underway. Thus, the aim of the present review is to assess the evidence for the efficacy and tolerability of paroxetine in comparison with TCAs, MAOIs, other SSRIs and newer agents in the acute-phase treatment of major depression.…”

Improving reproducibility by using high-throughput observational studies with empirical calibration

“…Our result set correctly identified findings (1) through ( 4), as discussed in the electronic supplementary material-implying substantial but not perfect agreement with the literature. Electronic supplementary material, figure S3 also compares our results for finding (1) to estimates from RCTs reported in a systematic review on the topic [25], showing agreement as well as greater precision in our estimates due to the much larger sample size.…”

Pitfalls in Geriatric Prescribing: Antidepressants and Extreme Sedation

“…On acute use, sertraline can selectively block serotonin reuptake and can increase serotonin stimulation of somatodendritic 5HT1 but has only weak effects on norepinephrine and neuronal dopamine uptake [11]. However, there is evidence that sertraline has a benefit over other classes of antidepressants in terms of safety or tolerability for the acute phase of severe depression treatment [12].…”

Paroxetine versus other anti-depressive agents for depression

“…To shed light on the field of AD trials and treatment of major depressive disorder, a group of researchers agreed to join forces under the rubric of the Meta-Analyses of New Generation Antidepressants Study Group (MANGA Study Group) to systematically review all available evidence for each specific newer antidepressant. We have up to now completed an individual review for fluoxetine , published the protocols for sertraline (Malvini 2006), fluvoxamine (Omori 2006) and mirtazapine (Watanabe 2007), and a number of other reviews are now underway. Thus, the aim of the present review is to assess the evidence for the efficacy and tolerability of paroxetine in comparison with TCAs, MAOIs, other SSRIs and newer agents in the acute-phase treatment of major depression.…”

Improving reproducibility by using high-throughput observational studies with empirical calibration

“…Our result set correctly identified findings (1) through ( 4), as discussed in the electronic supplementary material-implying substantial but not perfect agreement with the literature. Electronic supplementary material, figure S3 also compares our results for finding (1) to estimates from RCTs reported in a systematic review on the topic [25], showing agreement as well as greater precision in our estimates due to the much larger sample size.…”

Pitfalls in Geriatric Prescribing: Antidepressants and Extreme Sedation

“…On acute use, sertraline can selectively block serotonin reuptake and can increase serotonin stimulation of somatodendritic 5HT1 but has only weak effects on norepinephrine and neuronal dopamine uptake [11]. However, there is evidence that sertraline has a benefit over other classes of antidepressants in terms of safety or tolerability for the acute phase of severe depression treatment [12].…”

Paroxetine versus other anti-depressive agents for depression

“…To shed light on the field of AD trials and treatment of major depressive disorder, a group of researchers agreed to join forces under the rubric of the Meta-Analyses of New Generation Antidepressants Study Group (MANGA Study Group) to systematically review all available evidence for each specific newer antidepressant. We have up to now completed an individual review for fluoxetine , published the protocols for sertraline (Malvini 2006), fluvoxamine (Omori 2006) and mirtazapine (Watanabe 2007), and a number of other reviews are now underway. Thus, the aim of the present review is to assess the evidence for the efficacy and tolerability of paroxetine in comparison with TCAs, MAOIs, other SSRIs and newer agents in the acute-phase treatment of major depression.…”